Insider Buying: IDEXX Laboratories, Inc. (IDXX) Director Acquires 1,000 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Lawrence D. Kingsley bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was bought at an average cost of $178.05 per share, for a total transaction of $178,050.00. Following the completion of the transaction, the director now directly owns 4,558 shares of the company’s stock, valued at approximately $811,551.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of IDEXX Laboratories, Inc. (IDXX) traded up $1.03 during mid-day trading on Friday, reaching $182.48. 408,687 shares of the company’s stock were exchanged, compared to its average volume of 647,187. The firm has a market capitalization of $15,920.00, a PE ratio of 62.07, a price-to-earnings-growth ratio of 2.19 and a beta of 0.58. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. IDEXX Laboratories, Inc. has a 1 year low of $140.99 and a 1 year high of $198.73.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.04. The firm had revenue of $506.00 million for the quarter, compared to analysts’ expectations of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. IDEXX Laboratories’s revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.58 earnings per share. research analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on IDXX shares. Piper Jaffray Companies started coverage on shares of IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 target price on the stock. BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price on the stock in a research report on Tuesday, October 24th. Finally, Bank of America raised their target price on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $194.00.

Hedge funds have recently made changes to their positions in the business. Advisors Capital Management LLC acquired a new position in IDEXX Laboratories during the third quarter valued at approximately $262,000. Wells Fargo & Company MN lifted its position in IDEXX Laboratories by 7.8% during the third quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock valued at $52,706,000 after buying an additional 24,510 shares in the last quarter. Macquarie Group Ltd. raised its stake in shares of IDEXX Laboratories by 7.0% during the third quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock valued at $5,909,000 after purchasing an additional 2,500 shares during the period. Cabot Wealth Management Inc. purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $1,359,000. Finally, Atlantic Trust Group LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $65,381,000. 86.50% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: IDEXX Laboratories, Inc. (IDXX) Director Acquires 1,000 Shares of Stock” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/16/insider-buying-idexx-laboratories-inc-idxx-director-acquires-1000-shares-of-stock.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply